A phase 3 multicenter randomized double-blind placebo-controlled active reference (adalimumab) study evaluating the efficacy and safety of bimekizumab in the treatment of subjects with active psoriatic arthritis
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
